<b>Background/Objectives</b>: Precise intracellular delivery of chemotherapeutics remains a major challenge in HER2-positive breast cancer, where intratumoral heterogeneity and limited tissue penetration constrain efficacy. Here, ERBB2 is linked to breast cancer.